目的通过meta分析评价元认知疗法(MCT)对强迫症(OCD)的干预效果。方法在PubMed、Web of Science、ScienceDirect和PsycInfo数据库中检索相关文献,检索时间范围设定为2010年1月1日至2025年3月1日。纳入MCT治疗OCD的随机对照试验进行meta...目的通过meta分析评价元认知疗法(MCT)对强迫症(OCD)的干预效果。方法在PubMed、Web of Science、ScienceDirect和PsycInfo数据库中检索相关文献,检索时间范围设定为2010年1月1日至2025年3月1日。纳入MCT治疗OCD的随机对照试验进行meta分析,由2名研究者独立进行文献筛选及数据提取工作。根据Cochrane评价手册5.0.1版对纳入的文献进行质量评价,使用RevMan 5.3软件进行数据分析。采用耶鲁-布朗强迫量表评估强迫症状。结果检出2171篇文献,其中13篇符合纳入条件,共1111例患者。结果表明,MCT对OCD患者的强迫症状的改善与传统方法[暴露反应预防疗法(ERP)]相近,差异无统计学意义(均数差=0.04,95%CI-1.28~1.36,P=0.95)。结论MCT对改善OCD核心症状的疗效与ERP相当,且因其结构化、短程化(8~12周)的特点可能降低治疗脱落率。MCT为OCD治疗提供了有价值的ERP替代方案,尤其适合资源有限的医疗场景,但仍需更多高质量、多样化的临床研究进一步验证其优势。展开更多
Dear Editor,Social anxiety disorder(SAD)is a prevalent psychiatric disorder,characterized by persistent and excessive fear of social situations in which the individual may be scrutinized by others[1].Typically emergin...Dear Editor,Social anxiety disorder(SAD)is a prevalent psychiatric disorder,characterized by persistent and excessive fear of social situations in which the individual may be scrutinized by others[1].Typically emerging in late childhood or adolescence with potential lifelong persistence,SAD significantly impairs interpersonal relationships,educational attainment,and occupational performance[2].Furthermore,SAD demonstrates high comorbidity rates with other mental disorders,including anxiety disorders,substanceuse disorder,and major depressive disorder[3].Current therapeutic interventions remain limited,with suboptimal response to existing psychological and pharmacological treatments in many patients,while the pathological mechanisms underlying SAD continue to elude comprehensive understanding[4].Establishing appropriate animal models is essential to investigating SAD's neural mechanisms and pathological underpinnings and developing effective therapeutic interventions.展开更多
Dear Editor,The brain's capacity to rapidly detect environmental threats and mount appropriate adaptive responses is paramount for survival,a process intricately shaped by neuromodulatory systems[1].The neuropepti...Dear Editor,The brain's capacity to rapidly detect environmental threats and mount appropriate adaptive responses is paramount for survival,a process intricately shaped by neuromodulatory systems[1].The neuropeptide Parathyroid hormone 2(Pth2),also known as Tuberoinfundibular Peptide of 39 residues,is increasingly recognized for its role in modulating emotional states and stress-related behaviors,including anxiety[2,3].The medial paralemniscal nucleus(MPL),a brainstem structure uniquely positioned at the nexus of ascending sensory pathways(conveying somatosensory and auditory information)and descending limbic projections,exhibits a remarkably high density of Pth2-expressing neurons[46].This distinct neuroanatomical feature,combined with the MPL's established involvement in processing salient,often aversive,sensory inputs[4,6,7],strongly implicates MPLPth2 neurons as potential key integrators of noxious stimuli.展开更多
文摘目的通过meta分析评价元认知疗法(MCT)对强迫症(OCD)的干预效果。方法在PubMed、Web of Science、ScienceDirect和PsycInfo数据库中检索相关文献,检索时间范围设定为2010年1月1日至2025年3月1日。纳入MCT治疗OCD的随机对照试验进行meta分析,由2名研究者独立进行文献筛选及数据提取工作。根据Cochrane评价手册5.0.1版对纳入的文献进行质量评价,使用RevMan 5.3软件进行数据分析。采用耶鲁-布朗强迫量表评估强迫症状。结果检出2171篇文献,其中13篇符合纳入条件,共1111例患者。结果表明,MCT对OCD患者的强迫症状的改善与传统方法[暴露反应预防疗法(ERP)]相近,差异无统计学意义(均数差=0.04,95%CI-1.28~1.36,P=0.95)。结论MCT对改善OCD核心症状的疗效与ERP相当,且因其结构化、短程化(8~12周)的特点可能降低治疗脱落率。MCT为OCD治疗提供了有价值的ERP替代方案,尤其适合资源有限的医疗场景,但仍需更多高质量、多样化的临床研究进一步验证其优势。
基金the support of the research platform provided by Professor Zhi-Ying Wu’s research group at the Nanhu Brain-computer Interface Institutesupported by grants from the National Natural Science Foundation of China(32200822).
文摘Dear Editor,Social anxiety disorder(SAD)is a prevalent psychiatric disorder,characterized by persistent and excessive fear of social situations in which the individual may be scrutinized by others[1].Typically emerging in late childhood or adolescence with potential lifelong persistence,SAD significantly impairs interpersonal relationships,educational attainment,and occupational performance[2].Furthermore,SAD demonstrates high comorbidity rates with other mental disorders,including anxiety disorders,substanceuse disorder,and major depressive disorder[3].Current therapeutic interventions remain limited,with suboptimal response to existing psychological and pharmacological treatments in many patients,while the pathological mechanisms underlying SAD continue to elude comprehensive understanding[4].Establishing appropriate animal models is essential to investigating SAD's neural mechanisms and pathological underpinnings and developing effective therapeutic interventions.
基金supported by the Scientific and Technological Innovation 2030 Major Projects(STI2030-Major Projects 2021ZD0204002 and 2021ZD0204001)the National Natural Science Foundation of China(82201705)+2 种基金Natural Science Foundation of Jiangsu Province(BK2022040821)Medical Specialty Ascent Program of Southeast University(4060692202/005)the Fundamental Research Funds for the Central Universities(1124007126).
文摘Dear Editor,The brain's capacity to rapidly detect environmental threats and mount appropriate adaptive responses is paramount for survival,a process intricately shaped by neuromodulatory systems[1].The neuropeptide Parathyroid hormone 2(Pth2),also known as Tuberoinfundibular Peptide of 39 residues,is increasingly recognized for its role in modulating emotional states and stress-related behaviors,including anxiety[2,3].The medial paralemniscal nucleus(MPL),a brainstem structure uniquely positioned at the nexus of ascending sensory pathways(conveying somatosensory and auditory information)and descending limbic projections,exhibits a remarkably high density of Pth2-expressing neurons[46].This distinct neuroanatomical feature,combined with the MPL's established involvement in processing salient,often aversive,sensory inputs[4,6,7],strongly implicates MPLPth2 neurons as potential key integrators of noxious stimuli.
